Abstract
Stereotactic radiotherapy of oligometastases, mono- or hypofractionated, represents a fundamental change in the practice of the specialty as it was developed for a century. Despite the great heterogeneity of sites, techniques, and doses, most studies found a high local control rate, around 70 to 90% at 2 years, and reduced toxicity, around 5% of grade 3 at 2 years. Four main phase II and III trials are underway in France. Future research concerns the association of stereotactic radiotherapy with immunotherapy or different conventional chemotherapy protocols, the identification of the best clinical presentations, and optimization of fractionation and biological dose for poor prognosis localizations.
Keywords:
Oligometastases; Oligométastases; Radiothérapie stéréotaxique; Stereotactic radiotherapy.
Copyright © 2019 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Agents, Immunological / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Neoplasms / radiotherapy
-
Bone Neoplasms / secondary
-
Clinical Trials, Phase II as Topic*
-
Clinical Trials, Phase III as Topic*
-
Colorectal Neoplasms / drug therapy
-
Colorectal Neoplasms / radiotherapy
-
Combined Modality Therapy / methods
-
Forecasting
-
France
-
Humans
-
Immunotherapy
-
Kidney Neoplasms / drug therapy
-
Kidney Neoplasms / radiotherapy
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / radiotherapy
-
Male
-
Neoplasm Metastasis
-
Neoplasms / pathology
-
Neoplasms / radiotherapy*
-
Neoplasms / therapy
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / radiotherapy
-
Radiosurgery / methods*
-
Randomized Controlled Trials as Topic*
-
Squamous Cell Carcinoma of Head and Neck / drug therapy
-
Squamous Cell Carcinoma of Head and Neck / radiotherapy
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents, Immunological
-
durvalumab